advertisement
Abstract #8774 Published in IGR 5-1
The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo PArchives of Ophthalmology 2003; 121: 453-457
OBJECTIVE: To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). METHODS: In this crossover study, ten patients with POAG and ten with OHT were treated with latanoprost once a day, brimonidine twice a day, and a fixed combination of timolol and dorzolamide twice a day for one month. Four 24-hour tonometric curves were obtained for each patient. Intraocular pressure (IOP) was measured at 3, 6, and 9 a.m., noon, and 3, 6, and 9 p.m. and midnight, using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slitlamp. MAIN OUTCOME MEASURE: Reduction of circadian IOP. RESULTS: All the drugs significantly reduced IOP compared with the baseline at all times, except for brimonidine at midnight, and 3 and 6 a.m.. Latanoprost was more effective than brimonidine in lowering IOP at 3 and 6 a.m. and at 3 p.m. (p = 0.03), and the combination of timolol and dorzolamide was more effective than brimonidine at 3 and 9 a.m. (p = 0.04) and at 3 and 6 p.m. (p = 0.05) and more effective than latanoprost at 9 a.m. (p = 0.05). CONCLUSIONS: Latanoprost and the fixed combination of timolol and dorzolamide led to similar circadian reductions in IOP, whereas brimonidine was less effective, particularly during the night.
Dr. N. Orzalesi, Eye Clinic, Institute of Biomedical Sciences, University of Milan, San Paolo Hospital, Milan, Italy. lucamrosetti@libero.it
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
